Clinical trial · Observational
The STAR™ Tumor Ablation Registry
NCT02419703CI-TRIAL-00026931terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulty Enrolling
Summary
Brief summary (as posted)
Registry collecting data on use of The STAR™ Tumor Ablation System.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Lesions in Vertebral Bodies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STAR™ Tumor Ablation System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients receiving Targeted Radiofrequency Ablation (t-RFA)
- interventionNames
- Device: STAR™ Tumor Ablation System
Primary outcomes (1)
- measure
- Pain relief (Numerical Rating Pain Scale), post t-RFA
- timeFrame
- 1 month
- description
- measured by Numerical Rating Pain Scale (NRPS, 0-10 scale)
Secondary outcomes (1)
- measure
- Pain & Quality of Life Improvement (measured by the FACT G7 & Numerical Rating Pain Scale)
- timeFrame
- 1 week, 1 month, 3 month, 6 month, 12 month
- description
- measured by the FACT G7 \& Numerical Rating Pain Scale
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae (T1-L5) that will be treated with t-RFA using the STAR™ Tumor Ablation System. * Have signed informed consent Exclusion Criteria: * Subjects under 18 years old * Subjects with heart pacemakers, or other electronic device implants * Subjects intended for t-RFA in vertebral body levels C1-7
References
Publications (0)
Data not yet available
No reference posted for this study.